Key Takeaways:
- The PSA test is a simple blood draw that measures a protein produced by prostate cells; elevated levels can signal cancer but also benign conditions.
- Most men at average risk should start a screening conversation at age 50; those with family history or genetic risk factors should start at age 40 to 45.
- PSA velocity, meaning how quickly the number rises over time, often matters as much as the absolute value.
- An elevated PSA typically triggers further workup, not an immediate biopsy.
- Personalized screening plans, like those Catch provides, ensure you're tested at the right time and frequency for your specific risk profile.
Prostate cancer is the most commonly diagnosed cancer in American men, with about 1 in 8 receiving a diagnosis at some point in their lifetime. But here's what sets it apart from many other cancers: with the right screening at the right time, it is highly detectable, highly treatable, and in most cases survivable. The five-year survival rate for localized prostate cancer is nearly 100%.
The central tool in prostate cancer detection is the PSA test, a simple blood draw that can flag early warning signs long before any symptoms appear. If you're a man approaching middle age, or if you have a family history of the disease, understanding when to get screened and what your results mean is one of the most valuable things you can do for your long-term health.
What Is a PSA Test?
PSA stands for prostate-specific antigen, a protein produced by both normal and abnormal cells in the prostate gland. A small amount of PSA naturally circulates in the bloodstream, and a PSA test measures that level in a routine blood draw.
When PSA levels are higher than expected for your age, it can indicate that something is happening in the prostate, though not necessarily cancer. Elevated PSA can result from a benign enlarged prostate (benign prostatic hyperplasia, or BPH), prostatitis (inflammation of the prostate), recent physical activity or sexual activity, or prostate cancer. This is why a single PSA result is rarely used as a standalone diagnosis; it is a signal that warrants further investigation, not an answer in itself.
What Is Considered a Normal PSA Level?
PSA is measured in nanograms per milliliter (ng/mL) of blood. There is no universal "normal" threshold that applies to everyone, because PSA naturally rises with age and varies based on prostate size. That said, most clinicians use general reference ranges as a starting point:
- Under 4.0 ng/mL is generally considered low risk for most men
- 4.0 to 10.0 ng/mL is borderline, and often warrants additional testing
- Above 10.0 ng/mL is associated with a higher probability of cancer, though other causes remain possible
Importantly, about 15% of men with PSA levels below 4.0 ng/mL still have prostate cancer, and many men with elevated PSA do not. This is why context (your age, family history, rate of PSA change over time, and other factors) matters enormously when interpreting results.
What Is PSA Velocity?
PSA velocity refers to how quickly your PSA level is rising over time. A rapidly increasing PSA, even if the absolute number is still within a normal range, can be more clinically significant than a stable elevated reading. This is why tracking PSA results over multiple years, rather than relying on a single snapshot, is such an important part of prostate cancer surveillance. A sustained upward trend is a much stronger signal than any individual number taken in isolation.
When Should You Start Getting Screened?
The right starting age for prostate cancer screening depends heavily on your individual risk factors. The American Cancer Society recommends that men at average risk have a conversation with their doctor about the benefits and risks of PSA testing beginning at age 50. For men at higher risk, that conversation should happen earlier:
- Age 40 to 45 for men with a first-degree relative (father or brother) diagnosed with prostate cancer before age 65, or men with a known BRCA gene mutation
- Age 40 for men with more than one first-degree relative diagnosed with early-onset prostate cancer
African American men are also at significantly higher risk of developing prostate cancer and tend to be diagnosed at younger ages and with more aggressive disease. Earlier screening conversations are strongly recommended for this group.
Men with Lynch syndrome, a hereditary condition that increases risk across multiple cancer types, are also at elevated risk for prostate cancer and should discuss earlier screening with their physician.
How Often Should You Be Screened?
Screening frequency is typically determined by your baseline PSA level at the time of first testing:
- If your PSA is below 2.5 ng/mL, retesting every two years is usually appropriate
- If your PSA is above 2.5 ng/mL, annual testing is generally recommended
Your doctor may adjust this schedule based on your age, family history, prostate size, and the trajectory of past results. The goal is to identify meaningful changes early without subjecting you to unnecessary testing.
What Happens If Your PSA Is Elevated?
An elevated PSA result does not mean you have cancer. In most cases, the appropriate next step is a follow-up workup rather than an immediate biopsy. This may include:
- A repeat PSA test to confirm the reading before acting on it
- A free PSA ratio: measuring the proportion of PSA that is unbound in the blood, which can help distinguish cancer from benign causes
- A prostate MRI to look for suspicious lesions before committing to a biopsy
- A prostate biopsy if other findings suggest cancer is likely
The goal of this stepwise approach is to avoid unnecessary biopsies (which carry a small risk of infection and significant anxiety) while ensuring that men with true cancer are not missed.
What About the Digital Rectal Exam?
The digital rectal exam, in which a physician manually feels the prostate through the rectal wall, was historically paired with PSA testing as a standard part of screening. It remains useful in certain cases, particularly for detecting cancers located near the back of the prostate that may not produce elevated PSA, but its role has diminished as imaging technologies have improved. Many clinicians still include it as part of a comprehensive workup, especially for men with borderline PSA results or specific risk factors.
The Debate Around PSA Screening
PSA screening has been one of the more debated topics in cancer medicine, and it is worth understanding why. The concern is not that early detection is harmful; it is that some prostate cancers are slow-growing and may never cause symptoms or shorten life. The diagnostic process that follows an elevated PSA can sometimes lead to treatment for a cancer that would never have required it, and treatment for prostate cancer can carry significant side effects including urinary incontinence and erectile dysfunction.
Active surveillance, meaning closely monitoring low-risk cancers with regular PSA testing, imaging, and occasional biopsies rather than treating them immediately, has become a widely accepted approach that helps manage this balance. For men with slow-growing, localized prostate cancer, active surveillance allows them to avoid or delay treatment while maintaining close oversight.
The emerging consensus among major medical organizations is that individualized, shared decision-making between patient and physician is the right approach. Blanket recommendations for or against PSA screening have largely given way to personalized conversations about risk, values, and preferences.
How Catch Fits Into Your Prostate Cancer Screening Plan
Catch builds a personalized screening protocol for each member based on their unique risk profile, not generic age-based guidelines. For prostate cancer specifically, this means incorporating your family history, genetic risk factors, lifestyle variables, and PSA history to determine when you should start screening, how often, and what threshold should prompt additional workup.
Rather than applying a one-size-fits-all recommendation, Catch analyzes the same factors your physician would weigh and translates them into a clear, actionable plan. If your risk profile suggests earlier or more frequent testing, your protocol will reflect that. And as your PSA history develops over time, your plan evolves with it.
.svg)
